MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026
Statistically Significant Increase in Liver and Circulating FGF21 Expression Greater Glucose Lowering and Comparable Weight Loss vs. Retatrutide with Less Reliance on Appetite Suppression MetaVia Preparing to Initiate a Phase 2 Study in MetALD and ALD in the Second Half of 2027 CAMBRIDGE,...